New weekly shot aims to tame rare low-blood-sugar disease in kids and adults

NCT ID NCT04732416

First seen May 15, 2026 ยท Last updated May 15, 2026

Summary

This study tests a new drug called HM15136 in people aged 2 and older with congenital hyperinsulinism, a rare condition that causes dangerously low blood sugar. The drug is given as a weekly shot for 8 weeks, on top of their usual treatments. The goal is to see if it is safe and helps control blood sugar levels better.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CONGENITAL HYPERINSULINISM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Asan Medical Center

    Seoul, South Korea

  • Central Manchester University Hospitals NHS Foundation Trust - Royal Manchester Children's Hospital - Centre for Paediatrics and Child Health

    Manchester, United Kingdom

  • Great Ormond Street Hospital (GOSH) for Children NHS Foundation Trust

    London, United Kingdom

  • Hadassah Medical Center (HMC)

    Jerusalem, Israel

  • Otto-von-Guericke-Universitaet Magdeburg

    Magdeburg, Germany

  • Pusan National University Yangsan Hospital

    Pusan, South Korea

  • The Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania, 19104, United States

Conditions

Explore the condition pages connected to this study.